DrugCite
Search

LATISSE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Latisse Adverse Events Reported to the FDA Over Time

How are Latisse adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Latisse, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Latisse is flagged as the suspect drug causing the adverse event.

Most Common Latisse Adverse Events Reported to the FDA

What are the most common Latisse adverse events reported to the FDA?

Madarosis
741 (8.73%)
Ocular Hyperaemia
661 (7.79%)
Drug Ineffective
568 (6.69%)
Eye Pruritus
458 (5.39%)
Erythema Of Eyelid
428 (5.04%)
Wrong Technique In Drug Usage Proce...
409 (4.82%)
Eye Irritation
302 (3.56%)
Skin Hyperpigmentation
294 (3.46%)
Eyelids Pruritus
281 (3.31%)
Eyelid Oedema
278 (3.27%)
Trichorrhexis
238 (2.8%)
Show More Show More
Inappropriate Schedule Of Drug Admi...
168 (1.98%)
Incorrect Dose Administered
148 (1.74%)
Erythema
136 (1.6%)
Eye Swelling
136 (1.6%)
Dry Eye
130 (1.53%)
Hair Growth Abnormal
127 (1.5%)
Vision Blurred
126 (1.48%)
Therapeutic Response Decreased
120 (1.41%)
Drug Administered At Inappropriate ...
110 (1.3%)
Skin Discolouration
106 (1.25%)
Eye Pain
99 (1.17%)
Eye Discharge
91 (1.07%)
Eyelid Irritation
91 (1.07%)
Drug Administration Error
72 (.85%)
Lacrimation Increased
69 (.81%)
Pruritus
65 (.77%)
Scleral Hyperaemia
61 (.72%)
Burning Sensation
60 (.71%)
Blepharitis
56 (.66%)
Headache
55 (.65%)
Eyelid Pain
52 (.61%)
Abnormal Sensation In Eye
48 (.57%)
Dry Skin
38 (.45%)
Eyelid Exfoliation
36 (.42%)
Iris Hyperpigmentation
35 (.41%)
Eye Disorder
34 (.4%)
Hordeolum
33 (.39%)
Eyelash Discolouration
32 (.38%)
Foreign Body Sensation In Eyes
32 (.38%)
Hypersensitivity
29 (.34%)
Iris Disorder
29 (.34%)
Application Site Erythema
27 (.32%)
Skin Irritation
27 (.32%)
Blepharopachynsis
26 (.31%)
Therapy Cessation
26 (.31%)
Rash
24 (.28%)
Trichiasis
22 (.26%)
Application Site Pain
21 (.25%)
Asthenopia
21 (.25%)
Visual Acuity Reduced
21 (.25%)
Conjunctivitis
20 (.24%)
Eyelid Sensory Disorder
20 (.24%)
Hair Disorder
20 (.24%)
Hair Texture Abnormal
20 (.24%)
Visual Impairment
20 (.24%)
Eye Infection
19 (.22%)
Eyelid Ptosis
19 (.22%)
Muscle Twitching
19 (.22%)
Skin Exfoliation
19 (.22%)
Application Site Pruritus
18 (.21%)
Eyelid Disorder
18 (.21%)
Eyelid Margin Crusting
17 (.2%)
Nausea
17 (.2%)
Ocular Discomfort
17 (.2%)
Blepharospasm
16 (.19%)
Dark Circles Under Eyes
15 (.18%)
Pigmentation Disorder
15 (.18%)
Swelling Face
15 (.18%)
Accidental Exposure
14 (.16%)
Diplopia
13 (.15%)
Expired Drug Administered
13 (.15%)
Photophobia
13 (.15%)
Urticaria
13 (.15%)
Dizziness
12 (.14%)
Drug Interaction
12 (.14%)
Growth Of Eyelashes
12 (.14%)
Application Site Discolouration
11 (.13%)
Milia
11 (.13%)
Paraesthesia
11 (.13%)
Dermatitis
10 (.12%)
Drug Hypersensitivity
10 (.12%)
Mydriasis
10 (.12%)
Scleral Discolouration
10 (.12%)
Alopecia
9 (.11%)
Blister
9 (.11%)
Keratitis
9 (.11%)
Rash Erythematous
8 (.09%)
Skin Burning Sensation
8 (.09%)
Acne
7 (.08%)
Adverse Drug Reaction
7 (.08%)
Corneal Abrasion
7 (.08%)
Eye Haemorrhage
7 (.08%)
Injury Corneal
7 (.08%)
Migraine
7 (.08%)
Pain
7 (.08%)
Pregnancy
7 (.08%)
Sinus Disorder
7 (.08%)
Vomiting
7 (.08%)
Eczema Eyelids
6 (.07%)
Eyelid Vascular Disorder
6 (.07%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Latisse, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Latisse is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Latisse

What are the most common Latisse adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Latisse, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Latisse is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Latisse According to Those Reporting Adverse Events

Why are people taking Latisse, according to those reporting adverse events to the FDA?

Growth Of Eyelashes
2518
Hypotrichosis
409
Product Used For Unknown Indication
365
Drug Use For Unknown Indication
149
Madarosis
84
Eyelash Thickening
20
Show More Show More
Hair Growth Abnormal
19
Eyelash Discolouration
17
Trichorrhexis
6
Hair Disorder
5
Skin Wrinkling
5
Alopecia
3
Hypertrichosis
3
Therapeutic Skin Care Topical
3
Chemotherapy
3
Accidental Exposure
3
Dry Eye
2
Trichotillomania
2
Trichiasis
2
Alopecia Areata
2
Hair Texture Abnormal
2
Pruritus
1
Eye Swelling
1
Off Label Use
1
Dark Circles Under Eyes
1
Eyelids Pruritus
1
Migraine
1
Maternal Exposure Timing Unspecifie...
1
Menopausal Symptoms
1
Therapeutic Procedure
1
Blepharitis
1
Drug Administered At Inappropriate ...
1

Drug Labels

LabelLabelerEffective
LatissePhysicians Total Care, Inc.22-OCT-09
LatisseAllergan, Inc.30-NOV-12

Latisse Case Reports

What Latisse safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Latisse. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Latisse.